Agilent

The company's biggest revenue increase this quarter came from its diagnostics and genomics group, though its other businesses also posted increases.

Population Genetics was formed to commercialize the IP portfolio of Sydney Brenner focused on high sensitivity and high specificity NGS detection.

The test is now CE marked for use in identifying patients with urothelial cancer who are most likely to benefit from Opdivo therapy.

The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio. 

The companies will work together to develop a next-generation sequencing-based kit version of Agendia's molecular breast cancer diagnostics.

The firm saw 6 percent growth in its life sciences and applied markets group and 13 percent growth in its diagnostics and genomics group during the quarter.

The test can now be used to identify patients with squamous cell carcinoma of the head and neck who are likely to benefit from Opdivo therapy.